HomeAPN • JSE
add
Aspen Pharmacare Holdings Ltd
Nakaraang pagsara
ZAC 16,953.00
Sakop ng araw
ZAC 16,800.00 - ZAC 17,048.00
Sakop ng taon
ZAC 16,310.00 - ZAC 25,296.00
Market cap
75.47B ZAR
Average na Volume
1.38M
P/E ratio
17.06
Dividend yield
2.12%
Primary exchange
JSE
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(ZAR) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 11.78B | 9.30% |
Gastos sa pagpapatakbo | 2.36B | -3.24% |
Net na kita | 1.04B | -18.17% |
Net profit margin | 8.87 | -25.15% |
Kita sa bawat share | — | — |
EBITDA | 2.93B | 7.80% |
Aktuwal na % ng binabayarang buwis | 25.52% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(ZAR) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 12.34B | 13.06% |
Kabuuang asset | 139.16B | 3.63% |
Kabuuang sagutin | 54.29B | 13.00% |
Kabuuang equity | 84.86B | — |
Natitirang share | 444.21M | — |
Presyo para makapag-book | 0.89 | — |
Return on assets | 4.84% | — |
Return on capital | 5.56% | — |
Cash Flow
Net change in cash
(ZAR) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | 1.04B | -18.17% |
Cash mula sa mga operasyon | 1.88B | -1.21% |
Cash mula sa pag-invest | -1.65B | -79.92% |
Cash mula sa financing | -141.50M | 52.91% |
Net change in cash | -200.00M | -118.37% |
Malayang cash flow | 525.31M | -32.86% |
Tungkol
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
CEO
Itinatag
1850
Headquarters
Website
Mga Empleyado
9,109